Heartseed Inc.

PR

PR Prof. Massimiliano Gnecchi, Renowned Translational Cardiology Expert, Delivers Lecture at Heartseed.

PR Heartseed CEO Keiichi Fukuda Wins Japanese Society for Regenerative Medicine "Achievement Award"

PR Heartseed CEO Keiichi Fukuda Delivers Keynote on Regenerative Medicine at aichung Veterans General Hospital in Taiwan

PR Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

PR Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

PR Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

PR Heartseed Announces Positive 26-week Data for the First Patient in the Phase 1/2 Clinical Trial (LAPiS Study) Dosed With HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure

PR Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure

PR Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.

PR Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 - a cell therapy designed to restore heart function in people with advanced heart failure

1 2 3